Not exact matches
«We have identified a subgroup
of older patients at sufficiently low risk
of recurrence for whom omission
of postoperative
radiotherapy after breast - conserving surgery and
adjuvant endocrine therapy is a reasonable option.
Appearing in Lancet Oncology, long term results
of EORTC trial 22921 with 10.4 years median follow - up show that 5 - FU (fluorouracil) based
adjuvant chemotherapy after preoperative (chemo)-
radiotherapy for patients with cT3 - resectable T4 M0 rectal cancer does not improve survival or disease - free survival.
EORTC trial 22921 explored the value
of adding chemotherapy to preoperative
radiotherapy either concurrently, or as an
adjuvant, or both for patients with cT3 - resectable T4 M0 rectal cancer.
Adjuvant lymph - node field
radiotherapy versus observation only in patients with melanoma at high risk
of further lymph - node field relapse after lymphadenectomy (ANZMTG 01.02 / TROG 02.01): 6 - year follow - up
of a phase 3, randomised controlled trial.
Researchers are investigating nanoparticles for delivery
of immunostimulatory or immunomodulatory molecules in combination with chemo - or
radiotherapy or as
adjuvants to other immunotherapies.